BioNote

BioNote FCF CAGR 3Y

The FCF CAGR (3 Year) of BioNote (377740.KS) as of Oct 18, 2026 is -69.07 %.

FCF CAGR 3Y

-69.07 %

Last updated:

FCF CAGR (3 Year) of BioNote is 2025 -69.07 % . FCF CAGR (3 Year) of BioNote was 2024 - . It decreases by % lower compared to the previous year.

The BioNote FCF CAGR 3Y history

The BioNote FCF CAGR 3Y history
YEARFCF CAGR 3YYoY
-69.07 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BioNote Stock analysis

What does BioNote do? BioNote Inc., headquartered in Hwaseong, South Korea, operates in the Health Care sector, specifically within Biotechnology. The company develops and manufactures rapid diagnostic kits for humans and animals, including immunochemical and fluorescence-based diagnostic products. It also produces raw materials such as antigens, antibodies, and enzymes, along with semi-finished products for diagnostic use. Listed on December 22, 2022, BioNote focuses on veterinary and human diagnostic solutions. BioNote is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioNote stock

FCF CAGR (3 Year) of BioNote is -69.07 % in 2025.

On Eulerpool you can find the complete historical development of FCF CAGR (3 Year) BioNote since 2006 – with annual values, charts, and detailed analysis.

The 3-year FCF CAGR shows the compound annual growth rate of free cash flow over three years.

To evaluate FCF CAGR (3 Year)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF CAGR (3 Year).

FCF CAGR (3 Year)'s is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track FCF CAGR (3 Year)'s BioNote historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — BioNote

All Key Metrics — BioNote